142 related articles for article (PubMed ID: 19546757)
1. Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy.
Waters TP; Schultz BAH; Mercer BM; Catalano PM
Obstet Gynecol; 2009 Jul; 114(1):45-49. PubMed ID: 19546757
[TBL] [Abstract][Full Text] [Related]
2. 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
Eke AC; Sheffield J; Graham EM
Obstet Gynecol; 2019 Mar; 133(3):468-475. PubMed ID: 30741815
[TBL] [Abstract][Full Text] [Related]
3. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
Mainiero AD; Rouse DJ; Lopes V; Hughes BL
Obstet Gynecol; 2015 Jul; 126(1):103-8. PubMed ID: 26241262
[TBL] [Abstract][Full Text] [Related]
4. The rates of abnormal glucose challenge tests and gestational diabetes in women receiving 17α-hydroxyprogesterone caproate.
Wolfe K; Dearmond C; How H; Henderson ZT; Sibai B
Am J Perinatol; 2011 Dec; 28(10):741-6. PubMed ID: 21660898
[TBL] [Abstract][Full Text] [Related]
5. Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
Stetson B; Hibbard JU; Wilkins I; Leftwich H
Obstet Gynecol; 2016 Nov; 128(5):983-988. PubMed ID: 27741201
[TBL] [Abstract][Full Text] [Related]
6. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
[TBL] [Abstract][Full Text] [Related]
7. The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage.
Miller ES; Sakowicz A; Roy A; Liu LY; Yee LM
Am J Obstet Gynecol MFM; 2019 May; 1(2):144-147. PubMed ID: 32914089
[TBL] [Abstract][Full Text] [Related]
8. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
[TBL] [Abstract][Full Text] [Related]
9. Vaginal Progesterone Is Associated with Intrahepatic Cholestasis of Pregnancy.
Tsur A; Leonard SA; Kan P; Datoc IA; Girsen AI; Shaw GM; Stevenson DK; El-Sayed YY; Druzin ML; Blumenfeld YJ
Am J Perinatol; 2023 Aug; 40(11):1158-1162. PubMed ID: 37100422
[TBL] [Abstract][Full Text] [Related]
10. The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies.
Gyamfi C; Horton AL; Momirova V; Rouse DJ; Caritis SN; Peaceman AM; Sciscione A; Meis PJ; Spong CY; Dombrowski M; Sibai B; Varner MW; Iams JD; Mercer BM; Carpenter MW; Lo J; Ramin SM; O'Sullivan MJ; Miodovnik M; Conway D;
Am J Obstet Gynecol; 2009 Oct; 201(4):392.e1-5. PubMed ID: 19716543
[TBL] [Abstract][Full Text] [Related]
11. Maternal characteristics influencing the development of gestational diabetes in obese women receiving 17-alpha-hydroxyprogesterone caproate.
Egerman R; Ramsey R; Istwan N; Rhea D; Stanziano G
J Obes; 2014; 2014():563243. PubMed ID: 25405027
[TBL] [Abstract][Full Text] [Related]
12. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
Bustos ML; Caritis SN; Jablonski KA; Reddy UM; Sorokin Y; Manuck T; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM;
Am J Obstet Gynecol; 2017 Sep; 217(3):369.e1-369.e9. PubMed ID: 28522317
[TBL] [Abstract][Full Text] [Related]
13. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
14. In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring.
Murphy CC; Cirillo PM; Krigbaum NY; Cohn BA
Am J Obstet Gynecol; 2022 Jan; 226(1):132.e1-132.e14. PubMed ID: 34767803
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures.
Della Torre M; Enakpene C; Ravangard S; DiGiovanni L; Deyo K; Whelan A; Sutherland M; Fischer J
Am J Obstet Gynecol MFM; 2019 Nov; 1(4):100051. PubMed ID: 33345841
[TBL] [Abstract][Full Text] [Related]
16. The effect of esterases on 17alpha-hydroxyprogesterone caproate.
Yan R; Fokina V; Hankins GD; Ahmed MS; Nanovskaya TN
Am J Obstet Gynecol; 2008 Feb; 198(2):229.e1-5. PubMed ID: 17936237
[TBL] [Abstract][Full Text] [Related]
17. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
Stringer EM; Vladutiu CJ; Batra P; Stringer JSA; Menard MK
Obstet Gynecol; 2016 Dec; 128(6):1397-1402. PubMed ID: 27824772
[TBL] [Abstract][Full Text] [Related]
18. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo.
Northen AT; Norman GS; Anderson K; Moseley L; Divito M; Cotroneo M; Swain M; Bousleiman S; Johnson F; Dorman K; Milluzzi C; Tillinghast JA; Kerr M; Mallett G; Thom E; Pagliaro S; Anderson GD;
Obstet Gynecol; 2007 Oct; 110(4):865-72. PubMed ID: 17906021
[TBL] [Abstract][Full Text] [Related]
19. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
Odibo AO; Stamilio DM; Macones GA; Polsky D
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
[TBL] [Abstract][Full Text] [Related]
20. Intramuscular 17α-hydroxyprogesterone caproate to decrease preterm delivery in women with placenta praevia: a randomised controlled trial.
Shaamash AH; Ali MK; Attyia KM
J Obstet Gynaecol; 2020 Jul; 40(5):633-638. PubMed ID: 31670998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
